elranatamab
Term · Oncology and biomedicine · MLC-T-ONC-002754
A drug used to treat adults with multiple myeloma that came back or did not get better after treatment with at least four other anticancer therapies. These therapies had to include an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Elranatamab binds to a protein called CD3, which is found on T cells (a type of white blood cell), and to a protein called BCMA, which is found on myeloma cells and some types of immune cells. This may help the immune system kill cancer cells. Elranatamab is a type of bispecific T-cell engager. Also called Elrexfio.
| Identifier | MLC-T-ONC-002754 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | Elrexfio |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-002754",
"term": "elranatamab",
"field": "Oncology and biomedicine",
"definition": "A drug used to treat adults with multiple myeloma that came back or did not get better after treatment with at least four other anticancer therapies. These therapies had to include an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Elranatamab binds to a protein called CD3, which is found on T cells (a type of white blood cell), and to a protein called BCMA, which is found on myeloma cells and some types of immune cells. This may help the immune system kill cancer cells. Elranatamab is a type of bispecific T-cell engager. Also called Elrexfio.",
"synonyms": [
"Elrexfio"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/elranatamab/"
}
Record 6,555 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.